See more : PPB Group Berhad (4065.KL) Income Statement Analysis – Financial Results
Complete financial analysis of ProMIS Neurosciences, Inc. (PMN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProMIS Neurosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Qatar Navigation Q.P.S.C. (QNNS.QA) Income Statement Analysis – Financial Results
- Technology Minerals Plc (TM1.L) Income Statement Analysis – Financial Results
- Merck & Co., Inc. (6MK.DE) Income Statement Analysis – Financial Results
- Sondotécnica Engenharia de Solos S.A. (SOND6.SA) Income Statement Analysis – Financial Results
- U.S. Global Investors, Inc. (0LHX.L) Income Statement Analysis – Financial Results
ProMIS Neurosciences, Inc. (PMN)
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.14K | 1.40K | 920.18 | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
| Cost of Revenue | 10.44M | 21.78M | 5.85M | 3.18M | 4.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -10.44M | -21.78M | -5.84M | -3.18M | -4.73M | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
| Gross Profit Ratio | 0.00% | 0.00% | -71,796.88% | -227,041.82% | -514,509.20% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.88M | 16.09M | 4.95M | 2.50M | 3.63M | 5.44M | 3.15M | 1.39M | 763.96K | 1.27M | 1.77M | 2.04M | 3.25M | 3.62M | 3.27M | 6.06M | 2.95M | 944.20K |
| General & Administrative | 7.39M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.38M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 536.21K | 1.20M | 1.17M | 824.00K | 1.22M | 885.47K | 351.62K |
| Other Expenses | -5.81M | 115.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
| Operating Expenses | 8.45M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
| Cost & Expenses | 18.90M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
| Interest Income | 0.00 | 0.00 | 4.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 193.63K | 0.00 | 0.00 |
| Interest Expense | -201.39K | 282.06K | 415.03K | 0.00 | 0.00 | 0.00 | 5.65K | 15.89K | 23.98K | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.04K | 15.19K | 45.83K | 12.33K | 6.55K | 4.90K | 5.31K | 4.96K | 5.50K | 14.78K | 49.45K | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
| EBITDA | -17.81M | -29.88M | -9.33M | -4.43M | -5.66M | -7.46M | -4.78M | -2.55M | -1.51M | -2.88M | -2.02M | -2.15M | -2.49M | -3.13M | -4.61M | -3.90M | -6.82M | -3.62M |
| EBITDA Ratio | 0.00% | 0.00% | -100,802.23% | -315,985.67% | -614,617.22% | -2,139,026.95% | -60,699.29% | -127,551.65% | -9,929.36% | -1,508.22% | -4,408.57% | -2,730.51% | -261.17% | -2,617.02% | -2,013.48% | -1,470.16% | -1,645.59% | -2,724.12% |
| Operating Income | -18.90M | -23.38M | -8.25M | -4.44M | -5.66M | -7.46M | -4.78M | -2.56M | -1.51M | -2.04M | -2.19M | -2.56M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Operating Income Ratio | 0.00% | 0.00% | -101,363.57% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,766.72% | -127,799.59% | -10,519.49% | -1,519.23% | -4,510.18% | -2,813.90% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,382.95% |
| Total Other Income/Expenses | 1.39M | 7.20M | -1.50M | 1.22M | 0.00 | 0.00 | -5.65K | -11.82K | -17.28K | -853.75K | 0.00 | 40.59K | 13.50 | 3.34M | 0.00 | 4.08M | 3.32M | 1.98M |
| Income Before Tax | -17.51M | -18.06M | -9.24M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Income Before Tax Ratio | 0.00% | 0.00% | -113,562.83% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
| Income Tax Expense | -167.90K | -5.32M | 415.03K | 0.14 | 0.00 | -156.24K | 5.65K | 11.82K | 17.28K | 0.91 | -2.29K | 2.55M | 3.43M | 4.76M | 4.08M | 6.99M | 3.67M | 1.69M |
| Net Income | -17.51M | -12.74M | -9.66M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Net Income Ratio | 0.00% | 0.00% | -118,662.24% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
| EPS | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
| EPS Diluted | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
| Weighted Avg Shares Out | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
| Weighted Avg Shares Out (Dil) | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
Raised $20.4 million in PIPE gross proceeds to support continued development of Company's PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD),...
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development...
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
Presented c ompelling preclinical data support ing therapeutic potential of PMN310 to treat Alzheimer's disease , and the promise of disease prevention with a computationally derived A lzheimer's disease vaccine candidate at AAIC 2023
ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 17, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's...
ProMIS Announces Completion of Continuance
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neur osciences Inc. (TSX: PMN) (NASDAQ: PMN ) (“ProMIS” or the “Corporation”) is pleased to announce that it has completed its continuance (the “Continuance”) from the Canada Business...
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's...
ProMIS Neurosciences submits IND application for Alzheimer's treatment
ProMIS Neurosciences (TSX:PMN) told investors it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer's disease (AD). The development stage biotechnology company explained that PMN310 is a...
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's...
Source: https://incomestatements.info
Category: Stock Reports